In mice engrafted with wild-type EO771 cells, treatment with a Cxcr2 antagonist inhibited tumor growth, reduced myeloid suppressor and regulatory T cells with concomitant increases in macrophages, dendritic cells, and natural killer cells, and reduced tumor infiltration of CD8+ T cells. This evidence concerns the gene CXCR2 and neoplasm.